Graves’ Disease Clinical Trials

A Potential New Approach to Managing Graves’ Disease

Graves’ disease is a chronic autoimmune condition that causes the thyroid to produce too much hormone, leading to hyperthyroidism. It occurs when the body creates antibodies that overstimulate the thyroid gland. This condition is one of the most common causes of an overactive thyroid, especially in people with a family history of thyroid problems.

Early medical evaluation and treatment are important to manage symptoms and protect overall health.

Hightower Clinical is conducting a research study in adults with Graves’ disease (GD) who remain hyperthyroid despite antithyroid medication. This clinical study for Graves’ disease aims to evaluate the safety, tolerability, and effectiveness of an investigational study drug to help manage Graves’ disease effectively and improve patient outcomes.

Take Part in Advancing Graves’ Disease Research

Graves’ disease is a chronic autoimmune condition that is 5–10 times more common in women than men and is the leading cause of hyperthyroidism in developed countries. It most often affects adults between 30 and 60 years, and some patients experience spontaneous remission.

Hightower Clinical is conducting a study to evaluate the safety, tolerability, and effectiveness of a study drug in adults with Graves’ disease who remain hyperthyroid despite antithyroid medication. The trial aims to assess how well the study drug helps manage thyroid hormone levels and treatment response.

All study procedures and study-related treatment, including the investigational drug, are free of cost, and insurance is not required to participate.

The study doctor will take you through every step of the Clinical Trial before you decide to participate and will answer any questions you have about the study treatment.

What to Expect

If you decide to participate, you’ll first review and sign an Informed Consent Form that explains the study in detail. Our research team will walk you through the process, answer any questions, and ensure you understand your role before you choose to join or withdraw.

Once enrolled, you’ll be assigned to one of the two groups. One group receives a placebo, while the other receives the study drug. This is a double-blind study, meaning neither you nor the research team will know which treatment you are receiving.

Your participation may help future treatment options for autoimmune thyroid disorders become more effective.

All care related to the study is provided free of charge, with experienced physicians conducting thorough physical exams and evaluations.